Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human C5A Antibodies:
anti-Rat (Rattus) C5A Antibodies:
anti-Mouse (Murine) C5A Antibodies:
Go to our pre-filtered search.
Mouse (Murine) Monoclonal C5A Primary Antibody for ELISA - ABIN2688862
Hugli: Structure and function of the anaphylatoxins. in Springer seminars in immunopathology 1984
recombinant C5a potentiated TNFalpha (show TNF Antibodies)-induced NF-kappaB (show NFKB1 Antibodies) activation in renal tubular epithelial cells
tumoral C5a is an independent adverse prognostic biomarker for clinical outcome of Clear Cell Renal Cell Carcinoma (show MOK Antibodies) patients after nephectomy.
C5a synergises with P. aeruginosa LPS (show IRF6 Antibodies) in both PD-L1 (show CD274 Antibodies) expression and the production of IL-10 (show IL10 Antibodies) and TGF-beta (show TGFB1 Antibodies).
Up-regulation of granulocyte and monocyte CD11b (show ITGAM Antibodies) during plasma separation was C5-dependent.
This study provides the preclinical rationale for the combined blockade of PD-1 (show PDCD1 Antibodies)/PD-L1 (show CD274 Antibodies) and C5a to restore antitumor immune responses, inhibit tumor cell growth, and improve outcomes of patients with lung cancer
Diagnosis and therapeutic management of neonatal hemochromatosis (show HFE Antibodies) cannot only be based on C5b9 expression in liver samples as it is not specific of this disease.
C5a-C5aR enriched clear cell renal cell carcinoma (show MOK Antibodies) patients significantly had a poorer overall survival and recurrence free survival after nephrectomy.
The complement activation factors Bb, C3a, C5a, and MAC were increased significantly in early-onset severe pre-eclampsia (EOSPE) (all P<.01) and late-onset severe pre-eclampsia (LOSPE). (P value: .027, <.001, .001, and <.001, respectively) compared with E/L-control. C1q and C4d were increased significantly in LOSPE (P value: .003 and .014, respectively) compared with L-control.
C5a/C5aR pathway promotes gastric cancer pathogenesis by suppressing p21 (show CDKN1A Antibodies)/p-p21 (show CDKN1A Antibodies) expression via activation of PI3K (show PIK3CA Antibodies)/AKT (show AKT1 Antibodies) signaling.
Studies indicate that the complement response lie the active fragments, C3a (show C3 Antibodies) and C5a, acting through their specific receptors, C3aR (show C3AR1 Antibodies), C5aR1 (show C5AR1 Antibodies) and C5aR2 to direct the cellular response to inflammation.
The protein encoded by this gene is the fifth component of complement, which plays an important role in inflammatory and cell killing processes. This protein is comprised of alpha and beta polypeptide chains that are linked by a disulfide bridge. An activation peptide, C5a, which is an anaphylatoxin that possesses potent spasmogenic and chemotactic activity, is derived from the alpha polypeptide via cleavage with a convertase. The C5b macromolecular cleavage product can form a complex with the C6 complement component, and this complex is the basis for formation of the membrane attack complex, which includes additional complement components. Mutations in this gene cause complement component 5 deficiency, a disease where patients show a propensity for severe recurrent infections. Defects in this gene have also been linked to a susceptibility to liver fibrosis and to rheumatoid arthritis.
C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4
, C5a anaphylatoxin
, anaphylatoxin C5a analog
, complement C5